United Therapeutics Corporation (UTHR)
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade)
United Therapeutics is upgraded to 'Buy', as ralinepag's Phase 3 success de-risks the pipeline and positions UTHR for further upside. Ralinepag's blockbuster potential, TYVASO's IPF expansion, and a strategic shift away from royalty-heavy products underpin UTHR's attractive valuation. My base case fair value is ~$590/share, with scenario analysis indicating a solid margin of safety and upside toward $800 in bullish conditions.
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
United Therapeutics Corporation (UTHR) Presents at Leerink Global Healthcare Conference 2026 Transcript
United Therapeutics Corporation (UTHR) Presents at Leerink Global Healthcare Conference 2026 Transcript
United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript
United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript
UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance
United Therapeutics Q4 earnings beat estimates, Tyvaso DPI sales jump 24% despite revenue miss.
Compared to Estimates, United Therapeutics (UTHR) Q4 Earnings: A Look at Key Metrics
The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $7.7 per share, beating the Zacks Consensus Estimate of $6.78 per share. This compares to earnings of $6.19 per share a year ago.
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
